Background: Despite growing evidence supporting the efficacy of dupilumab in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), studies directly comparing biologic therapy with revision endoscopic sinus surgery remain limited. This study aimed to compare the effectiveness of dupilumab and revision endoscopic sinus surgery (ESS) in patients with recurrent CRSwNP. Methods: A retrospective cohort study was conducted in 50 patients with CRSwNP who had previously undergone at least two endoscopic sinus surgeries. Twenty-three patients received dupilumab, while twenty-seven underwent revision surgery. Changes in Nasal Polyp Score (NPS), quality of life assessed using the Sino-Nasal Outcome Test-22 (SNOT-22), and olfactory function evaluated with the Sniffin’ Sticks test were analyzed. Final clinical outcomes and the proportion of patients achieving very good disease control were also assessed. Results: Both treatment modalities improved disease control. However, dupilumab was associated with significantly greater reductions in NPS (median [IQR]: −6.00 [−6.00 to −5.00] vs. −4.00 [−6.00 to −3.00]; p = 0.012), larger improvements in SNOT-22 scores (−59.39 ± 12.14 vs. −21.37 ± 20.15; p < 0.001), and better recovery of olfactory function (+4.65 ± 2.79 vs. +2.19 ± 2.08; p = 0.001) compared with revision surgery. Analysis of final outcomes also favored dupilumab, with lower NPS scores (median [IQR]: 0.00 [0.00–1.00] vs. 1.00 [0.00–2.50]; p = 0.023), and better olfactory function (7.65 ± 3.11 vs. 4.78 ± 2.34; p < 0.001). Very good symptom control (SNOT-22 < 20) was achieved by 82.6% of patients treated with dupilumab compared with 7.4% of those undergoing revision surgery. Conclusions: Both revision surgery and dupilumab improved disease control in patients with CRSwNP. In this cohort, dupilumab was associated with greater reductions in disease severity, superior quality-of-life outcomes, and better olfactory function than revision endoscopic sinus surgery.
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease in which type 2 inflammation predominates in most patients in Western populations. Galectin-10 (Gal-10) and Charcot-Leyden crystals (CLCs), linked to eosinophil activation, cytolysis and eosinophil extracellular trap cell death (EETosis), have emerged as potential biomarkers and mediators of eosinophilic inflammation. This narrative review summarises current evidence on their biological role and clinical relevance in CRSwNP. The literature was identified through searches of PubMed/MEDLINE, Web of Science and Google Scholar, with emphasis on mechanistic studies, clinical investigations and recent evidence concerning type 2 inflammatory airway diseases. Available evidence suggests that Gal-10 and CLCs are associated with eosinophil activation and may contribute to persistent type 2 inflammation through epithelial injury, increased mucus viscosity, impaired mucociliary clearance, tissue remodelling and inflammatory amplification. Gal-10/CLCs may have value as investigational biomarkers of disease activity, postoperative recurrence and response to biologic therapy. Current biologics may indirectly modulate the Gal-10/CLC pathway by reducing eosinophil survival, recruitment or activation, although direct evidence remains limited. Gal-10 and CLCs are promising investigational biomarkers and mechanistically plausible therapeutic targets in CRSwNP. However, clinical application is limited by the lack of standardised analytical methods, validated cut-off values and prospective studies demonstrating incremental value beyond established biomarkers. Further research is required to clarify their role in stratification, prognosis and monitoring of biologic therapy.
Background: Hypereosinophilic syndrome (HES) is a heterogeneous group of disorders characterized by persistent eosinophilia and associated organ damage. Comorbid asthma in HES patients poses a therapeutic challenge, especially in cases resistant to standard eosinophil-lowering therapies. This case report describes the effective management of a 31-year-old patient with HES and asthma using dupilumab after unsuccessful treatments with mepolizumab and benralizumab. Case Presentation: A 31-year-old individual with a lifelong history of severe asthma and HES, presented with uncontrolled symptoms and 4 yearly exacerbations despite previous treatment with high-dose inhaled corticosteroids and two different biologics over the last 5 years: initially with mepolizumab (300-700mg q4w), which was withdrawn after 3 years due to diminishing efficacy and benralizumab (30mg q4w), which was ceased after 6 months due to lack of response. The patient exhibited poor asthma control and recurrent exacerbations, despite low blood eosinophil levels. Following a comprehensive evaluation, treatment with dupilumab was initiated. Results: Remarkable improvement was observed within first 2 weeks of starting dupilumab. At a 6-month checkpoint we observed a significant improvement in both ACQ (from 3.5 to 0.9) and AQLQ (2.3 to 5.9) scores. The patient did not experience any exacerbations and managed to reduce daily dose of oral corticosteroids from 25mg to 10mg of prednisone. No significant adverse effects or increase in eosinophil counts were noted during the treatment course.
Background/Objectives: Dupilumab blocks the interleukin-4 receptor alpha (IL-4Rα) subunit, thereby inhibiting IL-4- and IL-13-mediated signaling, and is an effective treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP). This study assessed clinical response and histopathological changes reflecting eosinophilic inflammation and tissue remodeling after 12 months of dupilumab therapy. Methods: This prospective pilot real-world study included 27 patients with severe CRSwNP. Paired sinonasal mucosal biopsies were obtained before treatment and after 12 months. Histopathological assessment included tissue eosinophilia, basement membrane thickness, subepithelial edema, tissue neutrophilia, and Charcot–Leyden crystals (CLCs). Clinical outcomes included Nasal Polyp Score (NPS), Sino-Nasal Outcome Test-22 (SNOT-22), and the 12-item Sniffin’ Sticks test. Results: Median NPS decreased from 6.0 [5.5–7.0] to 1.0 [1.0–1.0] (p < 0.001), SNOT-22 from 73.1 ± 15.7 to 14.9 ± 10.3 (p < 0.001), and olfactory scores increased from 2.85 ± 2.46 to 7.54 ± 3.19 (p < 0.001). Tissue eosinophils decreased from 122 [81–323] to 36 [19.5–76] cells/mm2 (p < 0.001), basement membrane thickness from 6.0 [4.15–7.5] to 4.0 [3.15–5.0] µm (p = 0.0019), and subepithelial edema from grade 2 [2–3] to 1 [1–1] (p < 0.001). Tissue neutrophil counts did not change significantly, while CLC prevalence decreased from 7/27 (25.9%) to 0/27 (0%; p = 0.0156; Holm-adjusted p = 0.0469). Conclusions: Twelve months of dupilumab therapy was associated with marked clinical improvement and significant histopathological changes in the sinonasal mucosa. These findings indicate that clinical improvement during treatment was accompanied by changes in eosinophilic inflammation and selected structural features of tissue remodeling.
1 January 2024 in Alergologia Polska - Polish Journal of Allergology
Ectoine is an organic chemical compound from the group of amino acids, produced by microorganisms to protect cells and their organelles from the adverse effects of the external environment. It has a wide range of applications in dermatology, allergy, laryngology, and ophthalmology. Additionally,...